Olga Golubnitschaja

List of Publications by Year
in descending order

147 papers	4,956 citations	76294 40 h-index	118793 62 g-index
167 all docs	167 docs citations	167 times ranked	3800 citing authors

#	Article	IF	Citations
1	Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA Journal, 2016, 7, 23.	3.3	292
2	General Report & Recommendations in Predictive, Preventive and Personalised Medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA Journal, 2012, 3, 14.	3.3	218
3	Flammer syndrome. EPMA Journal, 2014, 5, 11.	3.3	159
4	Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA Journal, 2017, 8, 23-33.	3.3	158
5	Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA Journal, 2019, 10, 365-381.	3.3	125
6	Predictive, Preventive and Personalised Medicine as the hardcore of â€˜Horizon 2020â€™: EPMA position paper. EPMA Journal, 2014, 5, 6.	3.3	123
7	Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention. Environmental Health and Preventive Medicine, 2018, 23, 36.	1.4	121
8	Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biology, 2016, 37, 12941-12957.	0.8	108
9	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. EPMA Journal, 2019, 10, 445-464.	3.3	96
10	Flavonoids against the Warburg phenotypeâ€"concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. EPMA Journal, 2020, 11, 377-398.	3.3	88
11	All around suboptimal health â€" a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine. EPMA Journal, 2021, 12, 403-433.	3.3	85
12	â€œPre-metastatic nichesâ€•in breast cancer: are they created by or prior to the tumour onset? â€œFlammer Syndromeâ€•relevance to address the question. EPMA Journal, 2017, 8, 141-157.	3.3	82
13	What Are the Biomarkers for Glaucoma?. Survey of Ophthalmology, 2007, 52, S155-S161.	1.7	79
14	Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification?. EPMA Journal, 2017, 8, 17-22.	3.3	73
15	Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA Journal, 2021, 12, 155-176.	3.3	71
16	Caution, â€œnormalâ€•BMI: health risks associated with potentially masked individual underweightâ€"EPMA Position Paper 2021. EPMA Journal, 2021, 12, 243-264.	3.3	70
17	Mass spectrometry analysis of human tear fluid biomarkers specificÂfor ocular and systemic diseases in the context of 3P medicine. EPMA Journal, 2021, 12, 449-475.	3.3	68
18	Increased Expression of Matrix Metalloproteinases in Mononuclear Blood Cells of Normal-Tension Glaucoma Patients. Journal of Glaucoma, 2004, 13, 66-72.	0.8	66

#	Article	IF	Citations
19	Carotenoids in Cancer Apoptosisâ€"The Road from Bench to Bedside and Back. Cancers, 2020, 12, 2425.	1.7	65
20	Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA Journal, 2011, 2, 197-210.	3.3	61
21	Cell-free nucleic acid patterns in disease prediction and monitoringâ€"hype or hope?. EPMA Journal, 2020, 11, 603-627.	3.3	58
22	Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. EPMA Journal, 2020, 11, 399-418.	3.3	58
23	Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA Journal, 2021, 12, 477-505.	3.3	58
24	Diabetes care in figures: current pitfalls and future scenario. EPMA Journal, 2018, 9, 125-131.	3.3	57
25	Genoprotective activities of plant natural substances in cancer and chemopreventive strategies inÂthe context of 3P medicine. EPMA Journal, 2020, 11, 261-287.	3.3	56
26	Premenopausal breast cancer: potential clinical utility of a multi-omics based machine learning approach for patient stratification. EPMA Journal, 2018, 9, 175-186.	3.3	54
27	Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA Journal, 2013, 4, 12.	3.3	53
28	Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management. International Journal of Molecular Sciences, 2019, 20, 2878.	1.8	53
29	MULTIOMIC PATTERNS IN BODY FLUIDS: TECHNOLOGICAL CHALLENGE WITH A GREAT POTENTIAL TO IMPLEMENT THE ADVANCED PARADIGM OF 3P MEDICINE. Mass Spectrometry Reviews, 2020, 39, 442-451.	2.8	53
30	â€œDry mouthâ€•and â€œFlammerâ€•syndromesâ€"neglected risks in adolescents and new concepts by predictive, preventive and personalised approach. EPMA Journal, 2018, 9, 307-317.	3.3	50
31	Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach. EPMA Journal, 2019, 10, 81-99.	3.3	50
32	Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?. EPMA Journal, 2017, 8, 119-127.	3.3	47
33	Covid-19 pandemic by the â€œreal-timeâ€•monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies. EPMA Journal, 2020, 11, 133-138.	3.3	47
34	Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progressionâ€"3PM pathways. EPMA Journal, 2021, 12, 559-587.	3.3	47
35	Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA Journal, 2010, 1, 263-272.	3.3	46
36	Liquid biopsy and multiparametric analysis in management of liver malignancies: new concepts of the patient stratification and prognostic approach. EPMA Journal, 2018, 9, 271-285.	3.3	46

#	Article	IF	Citations
37	Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine. EPMA Journal, 2021, 12, 265-305.	3.3	46
38	Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids, 2007, 32, 359-371.	1.2	44
39	Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach?. EPMA Journal, 2017, 8, 129-140.	3.3	44
40	Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice. EPMA Journal, 2019, 10, 317-335.	3.3	44
41	Mitochondrial impairments in aetiopathology of multifactorial diseases: common origin but individual outcomes in context of 3P medicine. EPMA Journal, 2021, 12, 27-40.	3.3	44
42	Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible?. EPMA Journal, 2010, 1, 237-244.	3.3	42
43	Individualised patient profile: clinical utility of Flammer syndrome phenotype and general lessons for predictive, preventive and personalised medicine. EPMA Journal, 2018, 9, 15-20.	3.3	42
44	Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA Journal, 2010, 1, 130-137.	3.3	41
45	Pregnancy-associated breast cancer: the risky status quo and new concepts of predictive medicine. EPMA Journal, 2018, 9, 1-13.	3.3	41
46	Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA Journal, 2010, 1, 3-12.	3.3	39
47	Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within â€˜Horizon 2020â€™. EPMA Journal, 2014, 5, 8.	3.3	39
48	Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. European Journal of Pharmacology, 2006, 542, 8-15.	1.7	38
49	DNA damage and expression of checkpoint genes p21WAF1/CIP1 and 14-3-3 Ïƒ in taurine-deficient cardiomyocytes. Biochemical Pharmacology, 2003, 66, 511-517.	2.0	37
50	Vaginal dryness: individualised patient profiles, risks and mitigating measures. EPMA Journal, 2019, 10, 73-79.	3.3	37
51	Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?. EPMA Journal, 2013, 4, 6.	3.3	36
52	Challenges in personalised management of chronic diseasesâ€"heart failure as prominent example to advance the care process. EPMA Journal, 2015, 7, 2.	3.3	35
53	Mitochondrial health quality control: measurements and interpretation in the framework of predictive, preventive, and personalized medicine. EPMA Journal, 2022, 13, 177-193.	3.3	35
54	Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clinical and Experimental Metastasis, 2016, 33, 743-755.	1.7	34

#	Article	IF	Citations
55	Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids, 2018, 50, 383-395.	1.2	34
56	10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) MedicineÂ- EPMA World Congress Supplement 2020. EPMA Journal, 2020, 11, 1-133.	3.3	34
57	Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. EPMA Journal, 2022, 13, 315-334.	3.3	34
58	Carotenoids in Cancer Metastasisâ€"Status Quo and Outlook. Biomolecules, 2020, 10, 1653.	1.8	32
59	Common origin but individual outcomes: time for new guidelines in personalized healthcare. Personalized Medicine, 2010, 7, 561-568.	0.8	30
60	EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA Journal, 2015, 6, 4.	3.3	30
61	Diabetes Mellitus as a Risk Factor for Cancer: Stress or Viral Etiology?. Infectious Disorders - Drug Targets, 2008, 8, 76-87.	0.4	30
62	Mitochondriopathies as a Clue to Systemic Disordersâ€"Analytical Tools and Mitigating Measures in Context of Predictive, Preventive, and Personalized (3P) Medicine. International Journal of Molecular Sciences, 2021, 22, 2007.	1.8	29
63	Sleep quality and COVID-19 outcomes: the evidence-based lessons in the framework of predictive, preventive and personalised (3P) medicine. EPMA Journal, 2021, 12, 221-241.	3.3	29
64	Mini-encyclopaedia of the wound healing - Opportunities for integrating multi-omic approaches into medical practice. Journal of Proteomics, 2018, 188, 71-84.	1.2	28
65	miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer. Future Oncology, 2018, 14, 1847-1867.	1.1	28
66	Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics, 2006, 6, 2924-2930.	1.3	27
67	Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Molecular Vision, 2009, 15, 2339-48.	1.1	27
68	Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment. Current Diabetes Reviews, 2010, 6, 42-51.	0.6	26
69	Postmenopausal breast cancer: European challenge and innovative concepts. EPMA Journal, 2017, 8, 159-169.	3.3	26
70	Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management. Journal of Clinical Medicine, 2020, 9, 2749.	1.0	26
71	Prostate cancer treatment costs increase more rapidly than for any other cancerâ€"how to reverse the trend?. EPMA Journal, 2022, 13, 1-7.	3.3	26
72	Optimal multiparametric set-up modelled for best survival outcomes in palliative treatment of liver malignancies: unsupervised machine learning and 3ÂPM recommendations. EPMA Journal, 2020, 11, 505-515.	3.3	25

#	Article	IF	Citations
73	Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. Molecular Vision, 2002, 8, 431-5.	1.1	25
74	The potential relationship between Flammer and SjÃ¶gren syndromes: the chime of dysfunction. EPMA Journal, 2017, 8, 333-338.	3.3	23
75	The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer. Biomedicine and Pharmacotherapy, 2018, 99, 51-58.	2.5	23
76	Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer, 2016, 16, 357.	1.1	22
77	Making a complex dental care tailored to the person: population health in focus of predictive, preventive and personalised (3P) medical approach. EPMA Journal, 2021, 12, 129-140.	3.3	20
78	Up-regulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment. Amino Acids, 2008, 34, 539-545.	1.2	19
79	Voice perturbations under the stress overload in young individuals: phenotyping and suboptimal health as predictors for cascading pathologies. EPMA Journal, 2020, 11, 517-527.	3.3	19
80	Disease proteomics reveals altered basic gene expression regulation in leukocytes of Normalâ€Tension and Primary Openâ€Angle glaucoma patients. Proteomics - Clinical Applications, 2007, 1, 1316-1323.	0.8	18
81	Protective Effects of Flavonoids Against Mitochondriopathies and Associated Pathologies: Focus on the Predictive Approach and Personalized Prevention. International Journal of Molecular Sciences, 2021, 22, 8649.	1.8	18
82	Molecular imaging of perfusion disturbances in glaucoma. Amino Acids, 2002, 23, 293-299.	1.2	17
83	Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes. Amino Acids, 2017, 49, 273-281.	1.2	17
84	Molecular imaging system for possible prediction of active retinopathy in patients with Diabetes mellitus. Amino Acids, 2005, 28, 229-237.	1.2	16
85	Time for new guidelines in advanced healthcare: the mission of The EPMA Journal to promote an integrative view in predictive, preventive and personalized medicine. EPMA Journal, 2012, 3, 5.	3.3	16
86	Challenging management of severe chronic disorders in acute pandemic situation: Chronic liver disease under COVID-19 pandemic as the proof-of-principle model to orchestrate the measures in 3PM context. EPMA Journal, 2021, 12, 1-14.	3.3	16
87	Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus. Infectious Disorders - Drug Targets, 2008, 8, 88-99.	0.4	16
88	Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology. International Journal of Molecular Sciences, 2020, 21, 7988.	1.8	15
89	Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer. Clinical Breast Cancer, 2020, 20, e711-e722.	1.1	15
90	Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine â€" comprehensive effects of phytochemicals in primary, secondary and tertiary care. EPMA Journal, 2022, 13, 461-486.	3.3	15

#	Article	IF	Citations
91	Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects. Cancers, 2021, 13, 3018.	1.7	14
92	Promoting predictive, preventive and personalised medicine in global scale: the EPMA World Congress 2011. EPMA Journal, 2011, 2, 1-3.	3.3	13
93	European strategies in predictive, preventive and personalised medicine: highlights of the EPMA World Congress 2011. EPMA Journal, 2011, 2, 315-332.	3.3	12
94	Opinion controversy to chromium picolinate therapy's safety and efficacy: ignoring 'anecdotes' of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?. EPMA Journal, 2012, 3, 11.	3.3	12
95	Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients. Current Proteomics, 2008, 5, 35-44.	0.1	11
96	Neurodegeneration: accelerated ageing or inadequate healthcare?. EPMA Journal, 2010, 1, 211-215.	3.3	11
97	Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. Personalized Medicine, 2016, 13, 455-467.	0.8	11
98	Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare. Cancers, 2020, 12, 1292.	1.7	10
99	Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?. Journal of Clinical Medicine, 2021, 10, 5124.	1.0	10
100	Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper. Cancers, 2022, 14, 675.	1.7	10
101	Activation of genes inducing cell-cycle arrest and of increased DNA repair in the hearts of rats with early streptozotocin-induced diabetes mellitus. Medical Science Monitor, 2006, 12, BR68-74.	0.5	10
102	Promoting predictive, preventive and personalised medicine: European event of global importance. EPMA Journal, 2011, 2, 131-136.	3.3	9
103	'Suspect molecular signature' in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA Journal, 2013, 4, 22.	3.3	9
104	Targeting phytoprotection in the COVID-19-induced lung damage and associated systemic effects—the evidence-based 3PM proposition to mitigate individual risks. EPMA Journal, 2021, 12, 325-347.	3.3	9
105	Wrist actigraphic approach in primary, secondary and tertiary care based on the principles of predictive, preventive and personalised (3P) medicine. EPMA Journal, 2021, 12, 349-363.	3.3	9
106	Down-regulation of microfilamental network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis. Cancer Genomics and Proteomics, 2009, 6, 31-40.	1.0	9
107	Flavonoids exert potential in the management of hypertensive disorders in pregnancy. Pregnancy Hypertension, 2022, 29, 72-85.	0.6	9
108	Differences in Gene Expression in Lymphocytes of Patients with High-tension, PEX, and Normal-tension Glaucoma and in Healthy Subjects. European Journal of Ophthalmology, 2013, 23, 841-849.	0.7	8

#	Article	IF	Citations
109	Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Personalized Medicine, 2016, 13, 469-484.	0.8	8
110	Changing Long-Held Beliefs Is Never Easy: A Proposal for Multimodal Approaches in Female Healthcare â€" An Integrative View. Advances in Predictive, Preventive and Personalised Medicine, 2012, , 251-268.	0.6	8
111	Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments. EPMA Journal, 2011, 2, 91-105.	3.3	7
112	Noninvasive subcellular imaging in breast cancer risk assessment: construction of diagnostic windows. Personalized Medicine, 2011, 8, 321-330.	0.8	7
113	Chromium-Picolinate Therapy in Diabetes Care: Molecular and Subcellular Profiling Revealed a Necessity for Individual Outcome Prediction, Personalised Treatment Algorithms & New Guidelines. Infectious Disorders - Drug Targets, 2011, 11, 188-195.	0.4	7
114	Paradigm Change from Curative to Predictive Medicine: Novel Strategic Trends in Europe. Croatian Medical Journal, 2009, 50, 596-597.	0.2	6
115	Chromium-Picolinate Therapy in Diabetes Care: Individual Outcomes Require New Guidelines and Navigation by Predictive Diagnostics. Infectious Disorders - Drug Targets, 2012, 12, 332-339.	0.4	5
116	Wound Healing: Proof-of-Principle Model for the Modern Hospital: Patient Stratification, Prediction, Prevention and Personalisation of Treatment. , 2019, , 357-366.		4
117	Individual Predispositions in Healthy Vasospastic Individuals: Patient Profiling for Targeted Prevention of â€œDown-Streamâ€•Pathologies as Cost-Effective Personalised Medicine. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 13-29.	0.6	4
118	Glaucomatous Optic Neuropathy: Risk Assessment and Potential Targets for Effective Prevention and Treatments Tailored to the Patient. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 187-201.	0.6	4
119	Superficial temperature distribution patterns before and after physical activity in school children are indicative for personalized exercise coaching and disease prevention. EPMA Journal, 2021, 12, 435-447.	3.3	4
120	Three Levels of Prediction, Prevention and Individualised Treatment Algorithms to Advance Diabetes Care: Integrative Approach. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 15-28.	0.6	3
121	Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Personalized Medicine, 2016, 13, 347-360.	0.8	3
122	Predictive, Preventive and Personalised Medicine as the Medicine of the Future: Anticipatory Scientific Innovation and Advanced Medical Services. , 2017, , 69-85.		3
123	Multiomic Signature of Glaucoma Predisposition in Flammer Syndrome Affected Individuals â€" Innovative Predictive, Preventive and Personalised Strategies in Disease Management. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 79-104.	0.6	3
124	Irradiated breast cancer patients demonstrate subgroup-specific regularities in protein expression patterns of circulating leukocytes. Cancer Genomics and Proteomics, 2007, 4, 411-8.	1.0	3
125	Effect of Everolimus versus Bone Marrow-Derived Stem Cells on Glomerular Injury in a Rat Model of Glomerulonephritis: A Preventive, Predictive and Personalized Implication. International Journal of Molecular Sciences, 2022, 23, 344.	1.8	3
126	Editorial Letter. EPMA Journal, 2010, 1, 523-524.	3.3	2

#	Article	IF	Citations
127	Global Figures Argue in Favour of Preventive Measures and Personalised Treatment to Optimise Inadequate Diabetes Care. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 1-13.	0.6	2
128	Cancer Predisposition in Diabetic Patients: Risk Assessment and Targeted Preventive Measures. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 355-370.	0.6	2
129	Time for New Guidelines in Handling of Neurodegenerative Disorders: Optimistic Versus Pessimistic Prognosis by Application of PPPM. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 3-9.	0.6	2
130	Flammer Syndrome, Disordered Eating and Microbiome: Interrelations, Complexity of Risks and Individual Outcomes. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 317-330.	0.6	2
131	Flammer Syndrome in the Context of Healing Impairments â€" Facts and Hypotheses for Multi-professional Consideration. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 193-203.	0.6	2
132	Flammer Syndrome in the Global Context â€" The â€œU-Shapeâ€•of Health Risks. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 1-7.	0.6	2
133	Diabetes Care: Risk Factors, Prediction, Prevention, and Individualized Treatment. Infectious Disorders - Drug Targets, 2008, 8, 68-69.	0.4	1
134	The EPMA Journal introduces a new type of research article dedicated to predictive, preventive and personalised medicine. EPMA Journal, 2013, 4, 11.	3.3	1
135	Flammer Syndrome: Psychological Causes and Consequences of Visual Impairment. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 29-77.	0.6	1
136	Patient-Centered Care: Making the Modern Hospital Truly Modern. , 2019, , 403-409.		1
137	â€œYoung Strokeâ€•Risks Potentially Linked to the Flammer Syndrome Phenotype: Facts and Hypotheses. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 165-181.	0.6	1
138	Relevance of Flammer Syndrome Phenotype to Metastatic Breast Cancer: Risks by Pre-metastatic Systemic Hypoxic Environment. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 243-263.	0.6	0
139	Recognition of Individual Risks by Analysis of Subcellular Imaging Insights into Chromium Picolinate Therapy in Pre/Diabetes Care, Search into Its Safety and Opinion Controversy. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 371-387.	0.6	0
140	Triple-Negative Breast Cancer with Pronounced Flammer Syndrome Phenotype â€" Case Report. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 277-285.	0.6	0
141	Specific Symptoms of Flammer Syndrome in Women Suffering from Vaginal Dryness: Individualised Patient Profiles, Risks and Mitigating Measures. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 125-134.	0.6	0
142	Interrelation Between Dry Mouth and Flammer Syndromes: Neglected Risks in Youth and New Concepts of Personalised Prevention. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 105-123.	0.6	0
143	Flammer Syndrome-Affected Individuals May Be Predisposed to Associated Pathologies Early in Life: Psychological and Psychiatric Aspects. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 19-28.	0.6	0
144	Flammer and SjÃ¶gren Syndromes: What and Why Is in Common?. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 183-192.	0.6	0

#	Article	IF	Citations
145	Relevance of Flammer Syndrome to the "Sleep-Wake" Rhythm: Possible Mechanisms, Risks and Preventive Strategies. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 135-143.	0.6	0
146	Feeling Cold and Other Underestimated Symptoms of Flammer Syndrome in Breast Cancer Diagnostics: Is Innovative Screening on the Horizon?. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 205-241.	0.6	0
147	Diabetes Forecasts and Statistics for the Coming Decades. , 2020, , 165-173.		0